Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. - Wikidata - wikimedia - TriplyDB

Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.

Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.

http://www.wikidata.org/entity/Q37064359

about

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus Vancomycin-intermediate Staphylococcus aureus in a home health-care patient Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.Coupling immunomagnetic separation on magnetic beads with matrix-assisted laser desorption ionization-time of flight mass spectrometry for detection of staphylococcal enterotoxin B Vancomycin resistance in staphylococci.Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus.Synthesis and evaluation of selected key methyl ether derivatives of vancomycin aglycon.Development and spread of bacterial resistance to antimicrobial agents: an overview.Identification of a novel methicillin-resistant Staphylococcus aureus epidemic clone in Córdoba, Argentina, involved in nosocomial infections.Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin.Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: a population-based assessment.A profile and spectrum of four cases of methicillin-resistant Staphylococcus aureus in a burns intensive care unit.Molecular epidemiology of clinical isolates of methicillin-resistant Staphylococcus aureus in Taiwan.Staphylococcus aureus with reduced susceptibility to vancomycin.VISA, hetero-VISA and VRSA: the end of the vancomycin era?Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA).Dalbavancin: a novel lipoglycopeptide antibacterial.Bacterial efflux pump inhibitors from natural sources.Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections.Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool.Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus.Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit.Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance.Mode of action of Van-M-02, a novel glycopeptide inhibitor of peptidoglycan synthesis, in vancomycin-resistant bacteria.Lack of relationship between purine biosynthesis and vancomycin resistance in Staphylococcus aureus: a cautionary tale for microarray interpretation.Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin.Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.

P2860

Q24646677-881C9522-5763-4911-9726-94E11737BF40 Q28362193-0E622337-3BC1-4072-A08C-F6955E11F8BF Q28366629-4619FCE2-EC0F-4617-ABD8-1F675334DEDC Q31704853-ECC4AF0D-DDDC-47B3-9C78-10F7D5F2EC5C Q33261667-08E570F4-7DB6-4662-AE55-1A79549156E3 Q33298021-AF27B996-7C3F-4802-93FC-F21C37364376 Q33906522-3FEF8D24-4A2D-4881-B7E5-1C138BF13C5C Q33938244-CA09D9B7-54FE-4ABD-99D3-4F37E254E406 Q33963573-63E3460A-D82F-455A-962A-A7D1F25F7CE7 Q33974326-23ACE8C3-806D-465E-BFB4-B8775C2DAB6D Q33978642-35D3C991-5E82-4567-BA2C-52BF1C52C7FA Q33978671-68B596D1-3825-4865-84DE-3B66723078B1 Q33981239-F09D5BD0-5860-4AB9-BACA-C4921ED3B6C5 Q33982746-F99B43DE-0736-4FAD-AE76-34F2670591BC Q34107062-5A4DAAF1-AE01-41E5-8B7B-389DDA0E0968 Q34142416-F56DA29B-7BE9-418F-BA49-D9EEA7FC117D Q34308628-3447F4AD-175A-4B85-83DA-6227E96A3DC0 Q34347837-CE1FE50C-A2CF-4EF3-A8EC-C0F31D17D450 Q34455317-764974C4-6C58-400D-BAE2-68B51811114A Q34823746-82CEE9D9-6E01-4739-B3DF-AB70CBD5718C Q34885043-48684D88-BD1E-4CC9-9052-591112C48094 Q35009236-4D802449-F973-4702-B23A-927D122BCD4D Q35279347-01636B78-871C-4920-8487-30554430A8BF Q35551962-812F4138-3ED7-4216-892C-79384D400195 Q35882353-5B2D210F-D21B-44A5-BB7B-4462CE34F379 Q36170611-2E7B4C1D-5765-45BC-915A-E65D48115909 Q36170841-C394AE83-7A65-4A68-A18B-F6B2E8FE496F Q36315377-E5ED7363-7715-4101-BDB1-59D67A74ECC7 Q36520635-43DCE563-FD62-4BF3-9DA5-CC3CFB8FE03E Q36673618-13D3A306-A15A-4642-BECB-00427382F255 Q36744825-9FD4DADD-A3EB-4595-8BD5-D4184972B060 Q36847287-090E2DD8-7B7B-4AE6-99A7-BD36560628B9 Q38225652-7205426A-5FDA-4D54-8F88-E37F4D84A518 Q39477498-1332E92E-9CD4-42E2-AD71-868E36432596 Q39677554-9E29D8C9-B320-4FBF-8709-FE60E025C3FC Q39755460-D36A2316-8C77-4155-BBAB-7851D3BCA7AA Q42111453-4F7F56FE-A01E-4ADB-989F-347B148CF654 Q42112243-A432ED2E-058A-4A1D-B3D4-68D850742FCB Q43754217-E8DFF93B-9729-4160-8D47-4C02F962EB18 Q46576587-DBD08D57-922F-4CA5-B911-1D65F8B8A6E1

P2860

Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.

http://www.wikidata.org/entity/Q37064359

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 1999

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Staphylococcus aureus with red ...... patient with fatal bacteremia.

@en

Staphylococcus aureus with red ...... patient with fatal bacteremia.

@nl

type

label

Staphylococcus aureus with red ...... patient with fatal bacteremia.

@en

Staphylococcus aureus with red ...... patient with fatal bacteremia.

@nl

prefLabel

Staphylococcus aureus with red ...... patient with fatal bacteremia.

@en

Staphylococcus aureus with red ...... patient with fatal bacteremia.

@nl

P1433

Q37064359-50BA4B03-03B9-4E8F-B5B5-96206B641568

P1476

Q37064359-D35EB5E8-660E-430F-86DC-C606ADF6F8D5

P2093

Q37064359-26F9DC6B-BC4E-4D18-B466-7E91A3DE5877

Q37064359-32043DEF-2BB0-4F41-91FA-FCF2FBB02742

Q37064359-767F2302-988F-4541-87F2-BB06EC0DB8D1

Q37064359-8FD1B72E-5057-4BCB-BFEB-166D98951B6E

Q37064359-9C8579FE-2A23-418C-A845-314BBA388525

Q37064359-B53DDE8D-22DB-47AC-965E-0AD16E01B80D

Q37064359-F6C333F2-74F3-49D2-82BD-8FABCCEFBB17

P2860

Q37064359-AB3C1F57-5F2F-4503-B583-C45B91913C88

P304

Q37064359-132A228A-6799-4FF9-A313-36B317B47908

P31

Q37064359-9c8530da-cf9a-4eeb-a6b0-d259888252ea

Q37064359-DE81C5A6-972B-4B23-9F8E-47139684E07E

P356

Q37064359-4FAFD8BC-66CF-473D-914C-82FD541B5B97

P433

Q37064359-ECE194A5-6645-4F63-BD91-55E87BBB5A69

P478

Q37064359-775F5D38-C0B4-4736-B0CC-7532EDA05023

P577

Q37064359-568FB5A9-0888-4A0C-90A0-31137E0E285B

P5875

Q37064359-A7F82AF5-6740-44EE-B7B3-6B5BB97F730D

P698

Q37064359-DAC8B946-F81F-47D1-97E4-C8E9D005EAA8

P921

Q37064359-F2A4DE2F-D935-4998-9086-EF27C2B40C46

P932

Q37064359-FBED772A-F196-4109-B068-E71BDC698DC5

P356

P1433

Emerging Infectious Diseases

P1476

Staphylococcus aureus with red ...... patient with fatal bacteremia.

@en

P2093

Ackman DM

http://www.w3.org/2001/XMLSchema#string

Hill BC

http://www.w3.org/2001/XMLSchema#string

Maupin PS

http://www.w3.org/2001/XMLSchema#string

McMath V

http://www.w3.org/2001/XMLSchema#string

Rotun SS

http://www.w3.org/2001/XMLSchema#string

Schoonmaker DJ

http://www.w3.org/2001/XMLSchema#string

Tenover FC

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides

P304

147-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3201/EID0501.990118

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

1999-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13208744

http://www.w3.org/2001/XMLSchema#string

P698

10081683

http://www.w3.org/2001/XMLSchema#string

P921

P932

2627701

http://www.w3.org/2001/XMLSchema#string